Laurent A. Décosterd

13.4k total citations · 2 hit papers
270 papers, 10.1k citations indexed

About

Laurent A. Décosterd is a scholar working on Infectious Diseases, Virology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Laurent A. Décosterd has authored 270 papers receiving a total of 10.1k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Infectious Diseases, 47 papers in Virology and 46 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Laurent A. Décosterd's work include HIV/AIDS drug development and treatment (77 papers), HIV Research and Treatment (47 papers) and Antibiotics Pharmacokinetics and Efficacy (40 papers). Laurent A. Décosterd is often cited by papers focused on HIV/AIDS drug development and treatment (77 papers), HIV Research and Treatment (47 papers) and Antibiotics Pharmacokinetics and Efficacy (40 papers). Laurent A. Décosterd collaborates with scholars based in Switzerland, United States and United Kingdom. Laurent A. Décosterd's co-authors include Thierry Buclin, Jérôme Biollaz, Amalio Telenti, Catia Marzolini, Chantal Csajka, Nicolas Widmer, Serge Leyvraz, Sara Colombo, Matthias Cavassini and Gilbert Greub and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of the American Chemical Society.

In The Last Decade

Laurent A. Décosterd

256 papers receiving 9.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

2001 687 citations Catia Marzolini, Laurent A. Décosterd et al. profile →
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

2002 535 citations Catia Marzolini, Thierry Buclin et al. profile →

Peers

Countries citing papers authored by Laurent A. Décosterd

Since Specialization

Citations

This map shows the geographic impact of Laurent A. Décosterd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurent A. Décosterd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurent A. Décosterd more than expected).

Fields of papers citing papers by Laurent A. Décosterd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurent A. Décosterd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurent A. Décosterd. The network helps show where Laurent A. Décosterd may publish in the future.

Co-authorship network of co-authors of Laurent A. Décosterd

This figure shows the co-authorship network connecting the top 25 collaborators of Laurent A. Décosterd. A scholar is included among the top collaborators of Laurent A. Décosterd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurent A. Décosterd. Laurent A. Décosterd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Therapeutic Drug Monitoring and Point-of-Care Technologies: Opportunities and Current Challenges 2025 ·Therapeutic Drug Monitoring ·Sandro Carrara, Nicolas Widmer, (unknown), (unknown), (unknown), Laurent A. Décosterd, Catia Marzolini, Thierry Buclin, Yann Thoma, Monia Guidi	1
2	Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome? 2025 ·Epilepsy & Behavior ·(unknown), Eva Choong, (unknown), (unknown), Pascal André, Andrea O. Rossetti, Thierry Buclin, Laurent A. Décosterd, Jan Nový	0
3	Therapeutic drug monitoring of Janus kinase inhibitors for precision dosing: where do we stand ? 2025 ·Expert Review of Clinical Pharmacology ·(unknown), Catia Marzolini, Laurent A. Décosterd, Monia Guidi, François Girardin	1
4	A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring 2025 ·Molecules ·Valentina D’Atri, F Corrado, (unknown), (unknown), Thomas Mercier, Monia Guidi, (unknown), Sylvain Blanchon, Angela Koutsokera, Michael Vogeser, Catia Marzolini, François Girardin, (unknown), (unknown), Isabelle Rochat, Alain Sauty, Laurent A. Décosterd, Eva Choong	0
5	Therapeutic Drug Monitoring for Precision Dosing of Janus Kinase Inhibitors: Protocol for a Prospective Observational Study 2025 ·JMIR Research Protocols ·(unknown), Laurent A. Décosterd, Monia Guidi, François Girardin	1
6	Is Nonsustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug Levels? 2024 ·Clinical Infectious Diseases ·(unknown), Catia Marzolini, Monia Guidi, Matthias Cavassini, Laurent A. Décosterd	2
7	Highly sensitive ultra-high-performance liquid chromatography coupled with tandem mass spectrometry method for the multiplex analysis of levosimendan and its metabolites OR-1855 and OR-1896 in human plasma 2024 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), (unknown), Thomas Mercier, Amarande Murisier, (unknown), David Haefliger, François Girardin, Marie‐Hélène Perez, Raphaël Giraud, Antoine Schneider, Thierry Buclin, Laurent A. Décosterd, Eva Choong, Françoise Livio	1
8	Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study 2024 ·Cancers ·(unknown), (unknown), (unknown), (unknown), Haïthem Chtioui, Laurent A. Décosterd, Dorothea Wagner, Marie Paule Schneider, Chantal Csajka, Monia Guidi	0
9	Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective 2023 ·Pharmaceutics ·(unknown), Pascal André, Yann Thoma, Nicolas Widmer, Dorothea Wagner, Laurent A. Décosterd, Thierry Buclin, Monia Guidi, Sandro Carrara	15
10	HDLs extract lipophilic drugs from cells 2022 ·Journal of Cell Science ·Adi Zheng, (unknown), Maria Georgieva, (unknown), (unknown), (unknown), (unknown), Thomas Mercier, Laurent A. Décosterd, Christian Widmann	4
11	Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland 2022 ·Pharmaceutics ·(unknown), (unknown), (unknown), Aline Munting, Matthias Cavassini, Dominique L. Braun, Huldrych F. Günthard, Katharina Kusejko, Bernard Surial, Hansjakob Furrer, Andri Rauch, (unknown), Alexandra Calmy, Marcel Stoeckle, Manuel Battegay, Catia Marzolini, Pascal André, Monia Guidi, Thierry Buclin, Laurent A. Décosterd, (unknown)	10
12	Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response 2022 ·European Journal of Neurology ·(unknown), Pascal André, Thierry Buclin, Laurent A. Décosterd, Andrea O. Rossetti, Jan Nový	5
13	Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer 2022 ·Pharmaceutics ·Perrine Courlet, (unknown), (unknown), Athina Stravodimou, (unknown), Haïthem Chtioui, Isabella Locatelli, Laurent A. Décosterd, (unknown), Benoı̂t Blanchet, Jérôme Alexandre, Dorothea Wagner, Khalil Zaman, Marie Paule Schneider, Monia Guidi, Chantal Csajka	6
14	Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP) 2022 ·British Journal of Clinical Pharmacology ·(unknown), Cédric Bovet, Regula Theurillat, Laurent A. Décosterd, Carlo R. Largiadèr, Jean‐Christophe Prost, Chantal Csajka, Daniela Bärtschi, Matthias Gückenberger, Roger von Moos, Sara Bastian, Markus Joerger, Ulrich Jaehde	1
15	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs 2021 ·European Journal of Clinical Pharmacology ·Perrine Courlet, Monia Guidi, (unknown), Matthias Cavassini, Marcel Stoeckle, Thierry Buclin, Catia Marzolini, Laurent A. Décosterd, Chantal Csajka	6
16	Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV 2020 ·Clinical Pharmacokinetics ·(unknown), Perrine Courlet, Laurent A. Décosterd, (unknown), Matthias Cavassini, Felix Stader, Marcel Stoeckle, Thierry Buclin, Catia Marzolini, Chantal Csajka, Monia Guidi	8
17	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial 2020 ·PLoS Medicine ·(unknown), Gilles Wandeler, Sabine Yerly, Annalisa Marinosci, Marcel Stoeckle, Enos Bernasconi, Dominique L. Braun, Pietro Vernazza, Matthias Cavassini, (unknown), Karin J. Metzner, Laurent A. Décosterd, Huldrych F. Günthard, Patrick Schmid, Andreas Limacher, Matthias Egger, Alexandra Calmy, (unknown)	20
18	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment 2019 ·British Journal of Clinical Pharmacology ·Perrine Courlet, Monia Guidi, (unknown), (unknown), Matthias Cavassini, Thierry Buclin, Catia Marzolini, Chin B. Eap, Laurent A. Décosterd, Chantal Csajka, (unknown)	8
19	Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy 2018 ·Nature Communications ·(unknown), L. Neff, (unknown), Hesham M. Ismail, Marta Sierra, Thomas Mercier, Laurent A. Décosterd, Jocelyn Laporte, Belinda S. Cowling, O.M. Dorchies, Léonardo Scapozza	26
20	Clinical pharmacokinetics of imatinib and its therapeutic relevance 2013 ·IRIS ·Nicolas Widmer, Verena Gotta, Amina Haouala, J.F. Blanc, Margaret von Mehren, Michel A. Duchosal, Serge Leyvraz, Chantal Csajka, Laurent A. Décosterd, Thierry Buclin	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact